GlassScriptPhysician profile
Luis Benjamin Flores
NPI 1760606123
$7,762.17
in general payments reported to CMS, 2019-2025
43 companies · $1,471 in 2025
The $1,471 reported for 2025 was more than what 92% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,064 · 2020: $646 · 2021: $1,129 · 2022: $939 · 2023: $1,316 · 2024: $1,197 · 2025: $1,471.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,984.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,983.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,329.59 | 2019-2025 | |
| Novo Nordisk INC | $886.46 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $508.28 | 2019-2025 | Evenity, Prolia, Repatha |
| Astrazeneca Pharmaceuticals LP | $471.76 | 2019-2025 | Airsupra, Farxiga, Lokelma |
| Amarin Pharma, INC. | $463.64 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $429.15 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Glaxosmithkline, LLC. | $381.91 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Otsuka America Pharmaceutical, INC. | $296.95 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Boehringer Ingelheim Pharmaceuticals, INC. | $283.80 | 2019-2024 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $228.86 | 2019-2025 | |
| Radius Health, INC. | $218.07 | 2019-2025 | Tymlos |
| Lilly USA, LLC | $201.02 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $200.88 | 2019-2025 | Trintellix |
| Gilead Sciences, INC. | $154.83 | 2019 | |
| Abbott Laboratories | $154.81 | 2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Flores listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.